January 2011
Ocular Surgery News;1/25/2011, Vol. 29 Issue 2, p35
Academic Journal
This section offers news briefs related to the ophthalmic industry. A definitive agreement signed by Novartis will allow the company to acquire 100% control of Alcon, which Novartis plans to designate as its new eye care division. Reicher Technologies announced that it has launched a redesigned and expanded company website aimed at improving the customer experience. Santen Pharmaceutical has introduced a diquafosol tetrasodium ophthalmic solution for treating dry eye in Japan, co-developed with Inspire Pharmaceuticals.


Related Articles

  • Ophthalmic Business. INDUSTRY NEWS IN BRIEF.  // Ocular Surgery News;9/25/2010, Vol. 28 Issue 18, p35 

    This section offers news briefs related to the ophthalmic equipment and ophthalmic drugs industries. A cooperative marketing agreement has been signed by TearLab Corp. and AMO Canada regarding their dry eye care products. SynergEyes has received approval from the U.S. Food and Drug...

  • FDA 510(k) Recommendations: Overview of Comments and Next Steps. Lincoln, John E. // Journal of Validation Technology;Spring2011, Vol. 17 Issue 2, p47 

    "Device Validation Forum" discusses regulatory requirements, scientific principles, strategies, and approaches associated with medical device validation that are useful to practitioners. We intend this column to be a valuable resource for daily work applications.

  • Industry Pipeline.  // Ocular Surgery News;6/25/2015, Vol. 33 Issue 12, p31 

    This section offers news briefs on the U.S. ophthalmic industry including the approval of Swiss-based medical company Alcon's new multifocal intraocular lens (IOL) for cataract treatment in U.S. patients by the U.S. Food and Drug Administration (FDA), the 501(k) clearance granted by the FDA to...

  • INDUSTRY NEWS.  // Orthopedics Today;Jan2013, Vol. 33 Issue 1, p32 

    The article offers latest industry news brief as of January 2013. Smith & Nephew has entered into an agreement to acquire all the assets of Healthpoint Biotherapeutics for 782 million dollars in cash. The Food and Drug Administration (FDA) has given 510 (k) clearance to aap Implantate AG for or...

  • Shire committed to ophthalmic space as dry eye drug emerges on FDA horizon. Dlugoss, Mark L. // Ophthalmology Times;Nov2015, Vol. 40 Issue 18, p8 

    An interview with Robert Dempsey, business unit head at Shire Pharmaceutical's Ophthalmics Business Unit, is presented. Dempsey highlights Shire's commitment to the eye space and its dedication to specialty pharmaceuticals. He explains why Shire entered the eye care market which he says has...

  • INDUSTRY NEWS IN BRIEF.  // Ocular Surgery News;3/25/2012, Vol. 30 Issue 6, p35 

    This section offers news briefs on the ocular surgery industry including the launches of the Femto LDV Z femtosecond laser platform models from Ziemer Ophthalmic Systems, of OjosSanos, a Spanish language version of the American Academy of Ophthalmologist's EyeSmart website, and of Refresh Optive...

  • Failure to heed incompatibility information can result in CSTD leaking hazardous drug. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;p990 

    The article focuses on the importance of using appropriate devices when working on hazardous drug formulations to protect healthcare workers from exposure. Topics covered include the use of closed-system drug transfer device (CSTD), incompatibility of the Tevadaptor CSTD from Teva Medical Ltd....

  • Veloxis' Phase 3 trial of LCP-Tacro in Stable Kidney Transplant Patients online in AJT.  // Transplant News;Jan2013, Vol. 23 Issue 1, p10 

    The article reports that Phase III trial of LCP-Tacro in stable kidney transplant patients, the 3001 study, by Veloxis Pharmaceuticals A/S has been published online in the American Journal of Transplantation (AJT).

  • University of Utah, Allergan collaborate on target-based clinical research. Hasson, Matt // Ocular Surgery News;4/25/2014, Vol. 32 Issue 8, p48 

    The article discusses the collaboration between Voyant Biotherapeutics of University of Utah's John A. Moran Eye Center and pharmaceutical company Allergan on research and development of disease-associated pathways, targets, and new therapeutic agents for age-related macular degeneration (AMD) ....


Read the Article


Sign out of this library

Other Topics